Facebook
Twitter
LinkedIn
Forward
Unlocking Optimal Strategies in Treating DED: Evaporation Is Key (Online CME Monograph)
Activity Description and Purpose
Dry eye disease (DED) is a common and multifactorial condition. The leading cause is meibomian gland dysfunction (MGD), which results in deficiency in the outer lipid layer of the tear film and increased evaporation. Advances in managing DED/MGD include the recent US Food and Drug Administration–approved perfluorohexyloctane with a novel mechanism of action. Lotilaner is a new option to address associated Demodex blepharitis. This educational activity presents an overview of DED/MGD pathophysiology and classification, results from clinical trials investigating new and emerging therapies, and case-based discussions in which experts share insights on developing targeted treatment regimens for managing DED/MGD. The desired results of this activity are to cement clinicians’ knowledge of the role of evaporation in the pathogenesis of MGD and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the function of the tear film in maintaining a healthy ocular surface
- Review clinical evidence of approved treatments for dry eye disease
- Design evidence-based treatment plans for patients with dry eye disease
Faculty
 | Eric D. Donnenfeld, MD (Chair) Clinical Professor of Ophthalmology New York University Langone Medical Center New York, New York Founding Partner Ophthalmic Consultants of Long Island and Connecticut Garden City, New York |
 | Marjan Farid, MD
|
 | Nicole R. Fram, MD Managing Partner Advanced Vision Care Los Angeles, California Assistant Adjunct Professor Moran Eye Center Salt Lake City, Utah |
 | Preeya K. Gupta, MD Medical Director Triangle Eye Consultants Raleigh, North Carolina Adjunct Associate Professor of Ophthalmology Cornea, Cataract, & Refractive Surgery Tulane University New Orleans, Louisiana |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Eric D. Donnenfeld, MD, is a consultant for AbbVie Inc, Alcon, Allegro Ophthalmics, LLC, Aurion Biotechnologies, Avellino, Bausch & Lomb Incorporated, BlephEx, BVI, CorneaGen, Covalent, Crystilex, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Labs, LLC, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen, LayerBio, Inc, LensGen, Mati Therapeutics, Inc, Melt Pharmaceuticals, Merck & Co., Inc, Mimetogen Pharmaceuticals, Nanowafer, NovaBay Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, OcuHub LLC, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, PogoTec, PRN, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, ReTEAR, Inc, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has stock options in Aurion Biotechnologies, Avedro, Inc, CorneaGen, Covalent, Crystilex, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen, LayerBio, Inc, LensGen, Mati Pharmaceuticals, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, NovaBay Pharmaceuticals, Inc, OcuHub LLC, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, ReTEAR, Inc, Strathspey Crown, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, and Visus Therapeutics.
Marjan Farid, MD, is a consultant for AbbVie Inc, AcuFocus, Inc*, Alcon, Aldeyra Therapeutics, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Dompé US, Inc*, Glaukos Corporation*, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is an advisory board member of AbbVie Inc, AcuFocus, Inc*, Alcon, Aldeyra Therapeutics, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Dompé US, Inc*, Glaukos Corporation*, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; and has stocks or stock options in Kala Pharmaceuticals.
Nicole R. Fram, MD, is a consultant for Alcon, Aldeyra Therapeutics, Aurion Biotechnologies, CorneaGen, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, RxSIGHT, and Zeiss; is an advisory board member of Aurion Biotechnologies, CorneaGen, Johnson & Johnson Vision Care, New World Medical, Inc, Ocular Science, and Orasis Pharmaceuticals; is on the speakers bureau for Alcon and Johnson & Johnson Vision Care; and is a contracted researcher for Ocular Therapeutix, Inc, and Zeiss.
Preeya K. Gupta, MD, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics, Azura Ophthalmics, Carl Zeiss Meditec, Inc, Expert Opinion MD, Hanall Biopharma, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, New World Medical, Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sight Sciences, SpyGlass Ophthalmics, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, TearClear, TearLab Corporation, TissueTech, Inc, and Visionology; has stock options that have not been exercised in Azura Ophthalmics, Expert Opinion MD, Orasis Pharmaceuticals, SpyGlass Ophthalmics, Surface Pharmaceuticals Inc, TearClear, and Visant Medical, Inc; and has stocks or stock options in Oyster Point Pharma, Inc, Tarsus Pharmaceuticals, Inc, and Visionology.
* The financial relationship existed during the past 24 months but has now ended.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Cheryl Guttman Krader has individual stocks in AbbVie Inc and Johnson & Johnson Vision Care, Inc.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
To view the MedEdicus privacy policy, visit http://mededicus.com/privacy-policy.php.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Bausch & Lomb Incorporated, or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 302.5b
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation